Achieving Medication Safety During Acute Kidney Injury
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01134900|
Recruitment Status : Completed
First Posted : June 2, 2010
Results First Posted : February 27, 2012
Last Update Posted : February 27, 2012
|Condition or disease||Intervention/treatment||Phase|
|Kidney Failure, Acute||Other: Pharmacy Dashboard Review and Intervention||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||540 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Achieving Medication Safety During Acute Kidney Injury: The Impact of Clinical Decision Support and Real-Time Pharmacy Surveillance|
|Study Start Date :||June 2010|
|Actual Primary Completion Date :||August 2010|
|Actual Study Completion Date :||August 2010|
Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.
Other: Pharmacy Dashboard Review and Intervention
Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
No Intervention: Control
Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.
- Adverse Drug Events or Potential Adverse Drug Events [ Time Frame: Until patient discharge (~2 week average) ]Our primary outcome measured the rate of AKI-related ADEs and pADEs. We defined pADEs as incidents with the potential for injury related to a drug, such as use of a non-steroidal anti-inflammatory drug for at least 24 hours, and ADEs as injuries resulting from the administration of a drug, such as a toxic vancomycin trough level or a bleed after administration of enoxaparin. We measured outcomes after completion of the inpatient encounter (either by death or discharge); pADEs or ADEs occurring after patient discharge were not included in the analysis.
- Time to Provider Response [ Time Frame: Until patient discharge (~2 week average) ]Time from study event to modification or discontinuation of targeted medication
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01134900
|United States, Tennessee|
|Vanderbilt University Medical Center|
|Nashville, Tennessee, United States, 37235|
|Principal Investigator:||Allison B McCoy, PhD||The University of Texas Health Science Center at Houston (UTHealth)|
|Principal Investigator:||Josh F Peterson, MD, MPH||Vanderbilt University Medical Center|